πŸ‡ΊπŸ‡Έ FDA
Patent

US 10280422

MiR-92 inhibitors and uses thereof

granted A61PA61P17/02A61P3/10

Quick answer

US patent 10280422 (MiR-92 inhibitors and uses thereof) held by MIRAGEN THERAPEUTICS, INC. expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MIRAGEN THERAPEUTICS, INC.
Grant date
Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
42
CPC classes
A61P, A61P17/02, A61P3/10, A61P9/00, A61P9/10